{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:39:55Z","timestamp":1792687195204,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi G. D'Annunzio Chieti Pescara"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) increase haematocrit and may cause erythrocytosis, creating uncertainty in type 2 diabetes management. Most available data derive from administrative registries or mixed, non-diabetic and\/or non-European population. This study aimed to assess the onset, clinical characteristics and management outcomes of people with type 2 diabetes developing SGLT2i-associated erythrocytosis in a routine clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, single-centre cohort study included adults with type 2 diabetes who developed at least one episode of erythrocytosis (haematocrit\u2009\u2265\u200948% in women, \u2265\u200949% in men) during the first year after initiation of SGLT2i therapy. Haemoglobin and haematocrit were collected at baseline, at erythrocytosis onset, and at 6 and 12 months with the first erythrocytosis episode defined as the \u201cindex date\u201d. No time effect or effect modification across predictive variables was observed. Management included no intervention in 84.1%, SGLT2i discontinuation in 5.3%, and phlebotomy in 4.5%. JAK2 V617F testing was performed in 19 cases, yielding negative results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Erythrocytosis was detected in 3.4% of subjects (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009132 out of 3,848). The cohort was predominantly male (87.9%), with a median age of 68.4 years and diabetes duration of 10.5 years. Cardiovascular comorbidities were common. The median time from SGLT2i initiation to erythrocytosis was 11.9 months. Over 12 months, haematocrit and haemoglobin levels remained stable, with no thrombotic events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SGLT2i-associated erythrocytosis is an uncommon, stable, and seemingly low-risk phenomenon. However, it may trigger unnecessary interventions, including treatment discontinuation. These findings highlight a gap between the benign nature of this effect and real-world practice, supporting the need for evidence-based, multidisciplinary guidelines to preserve SGLT2i cardiorenal benefits and optimise patient management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00592-026-02762-w","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:09:12Z","timestamp":1786964952000},"page":"1923-1931","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium\u2013glucose cotransporter 2 inhibitor-associated erythrocytosis in type 2 diabetes: a retrospective cohort study"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-7439","authenticated-orcid":false,"given":"Maria Pompea Antonia","family":"Baldassarre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2117-3416","authenticated-orcid":false,"given":"Federica","family":"Carrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5726-0413","authenticated-orcid":false,"given":"Andrea","family":"Sablone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9217-1506","authenticated-orcid":false,"given":"Annalisa","family":"Marotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1225-0902","authenticated-orcid":false,"given":"Paola","family":"Ranalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-2039","authenticated-orcid":false,"given":"Fabrizio","family":"Febo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1885-451X","authenticated-orcid":false,"given":"Agostino","family":"Consoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1748-1931","authenticated-orcid":false,"given":"Marta","family":"Di Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8692-8827","authenticated-orcid":false,"given":"Gloria","family":"Formoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"20","key":"2762_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/BLOOD-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/BLOOD-2016-03-643544","journal-title":"Blood"},{"issue":"24","key":"2762_CR2","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.1182\/BLOODADVANCES.2020003323","volume":"4","author":"HJCM Wouters","year":"2020","unstructured":"Wouters HJCM, Mulder R, Van Zeventer IA et al (2020) Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis. Blood Adv 4(24):6353\u20136363. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2020003323","journal-title":"Blood Adv"},{"key":"2762_CR3","doi-asserted-by":"publisher","first-page":"154918","DOI":"10.1016\/J.METABOL.2021.154918","volume":"126","author":"H Liu","year":"2022","unstructured":"Liu H, Sridhar VS, Boulet J et al (2022) Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism 126:154918. https:\/\/doi.org\/10.1016\/J.METABOL.2021.154918","journal-title":"Metabolism"},{"issue":"6","key":"2762_CR4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/J.JACBTS.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S (2020) Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci 5(6):632\u2013644. https:\/\/doi.org\/10.1016\/J.JACBTS.2020.02.004","journal-title":"JACC Basic Transl Sci"},{"issue":"12","key":"2762_CR5","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1002\/AJH.70118","volume":"100","author":"N Gangat","year":"2025","unstructured":"Gangat N, Szuber N, Tefferi A (2025) JAK2 Unmutated Erythrocytosis: 2026 Update on Diagnosis and Management. Am J Hematol 100(12):2333\u20132354. https:\/\/doi.org\/10.1002\/AJH.70118","journal-title":"Am J Hematol"},{"key":"2762_CR6","doi-asserted-by":"publisher","unstructured":"Lee JY, Lee JH, Jung EJ et al (2025) Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study. Cardiovasc Diabetol 24(1). https:\/\/doi.org\/10.1186\/S12933-025-02805-6","DOI":"10.1186\/S12933-025-02805-6"},{"key":"2762_CR7","doi-asserted-by":"publisher","unstructured":"Mohamed AA, Andersen CF, Christensen DM et al (2025) Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study. Cardiovasc Diabetol 24(1). https:\/\/doi.org\/10.1186\/S12933-025-02871-W","DOI":"10.1186\/S12933-025-02871-W"},{"key":"2762_CR8","doi-asserted-by":"publisher","unstructured":"Lewis M, Burrack N, Heymann A, Grossman A, Neuman T, Abuhasira R (2025) Sodium-Glucose Cotransporter 2 Inhibitors, Erythrocytosis, and Thrombosis in Adults With Type 2 Diabetes. JAMA Netw Open 8(6). https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2025.17086","DOI":"10.1001\/JAMANETWORKOPEN.2025.17086"},{"issue":"7","key":"2762_CR9","doi-asserted-by":"publisher","first-page":"E165","DOI":"10.1002\/AJH.26933","volume":"98","author":"N Gangat","year":"2023","unstructured":"Gangat N, Abdallah M, Szuber N et al (2023) Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases. Am J Hematol 98(7):E165\u2013E167. https:\/\/doi.org\/10.1002\/AJH.26933","journal-title":"Am J Hematol"},{"issue":"17","key":"2762_CR10","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","volume":"139","author":"M Sano","year":"2019","unstructured":"Sano M, Goto S (2019) Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 139(17):1985\u20131987. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038881","journal-title":"Circulation"},{"key":"2762_CR11","doi-asserted-by":"publisher","unstructured":"Wong CKH, Lau KTK, Tang EHM et al (2022) Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study. Cardiovasc Diabetol 21(1). https:\/\/doi.org\/10.1186\/S12933-022-01520-W","DOI":"10.1186\/S12933-022-01520-W"},{"issue":"11","key":"2762_CR12","doi-asserted-by":"publisher","first-page":"E639","DOI":"10.1002\/AJH.24873","volume":"92","author":"I Bertozzi","year":"2017","unstructured":"Bertozzi I, Ruggeri M, Nichele I, Biagetti G, Cosi E, Randi ML (2017) Thrombotic and hemorrhagic complications in idiopathic erythrocytosis. Am J Hematol 92(11):E639\u2013E641. https:\/\/doi.org\/10.1002\/AJH.24873","journal-title":"Am J Hematol"},{"issue":"2","key":"2762_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/S00277-015-2548-Z","volume":"95","author":"ML Randi","year":"2016","unstructured":"Randi ML, Bertozzi I, Cosi E, Santarossa C, Peroni E, Fabris F (2016) Idiopathic erythrocytosis: a study of a large cohort with a long follow-up. Ann Hematol 95(2):233\u2013237. https:\/\/doi.org\/10.1007\/S00277-015-2548-Z","journal-title":"Ann Hematol"},{"key":"2762_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejim.2022.09.004","volume":"107","author":"V Ernest","year":"2023","unstructured":"Ernest V, Abbou N, Tichadou A, Arcani R, Venton G (2023) Characteristics of JAK2 unmutated erythrocytosis: Distinctive traits between polycythemia vera and non-polycythemia vera patients. Eur J Intern Med 107:113\u2013115. https:\/\/doi.org\/10.1016\/j.ejim.2022.09.004","journal-title":"Eur J Intern Med"},{"issue":"26","key":"2762_CR15","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/BLOOD.2021013996","volume":"138","author":"N Gangat","year":"2021","unstructured":"Gangat N, Szuber N, Alkhateeb H, Al-Kali A, Pardanani A, Tefferi A (2021) JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy. Blood 138(26):2886\u20132889. https:\/\/doi.org\/10.1182\/BLOOD.2021013996","journal-title":"Blood"},{"issue":"2","key":"2762_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/BJH.15647","volume":"184","author":"MFF McMullin","year":"2019","unstructured":"McMullin MFF, Mead AJ, Ali S et al (2019) A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline. Br J Haematol 184(2):161\u2013175. https:\/\/doi.org\/10.1111\/BJH.15647","journal-title":"Br J Haematol"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02762-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-026-02762-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02762-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:02:34Z","timestamp":1792684954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-026-02762-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["2762"],"URL":"https:\/\/doi.org\/10.1007\/s00592-026-02762-w","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no conflicts of interest and declare that they have no relationships or activities that could be perceived as influencing the content of this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}